The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The CDC and FDA advise against Ixchiq chikungunya vaccine for American travellers aged 60 and above. This is due to reported ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 and older, including death.

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

May 7 (Reuters) - The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's (VLS.PA), opens new tab chikungunya vaccine after reports of serious side ...